Literature DB >> 9880010

Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation.

R Braun1, L A Babiuk.   

Abstract

One anticipated advantage of DNA immunization is the potential to create multivalent vaccines. We have examined the effects of mixing plasmids into single formulations using plasmids expressing four different membrane bound glycoproteins from bovine herpesvirus-1 (BHV-1), bovine parainfluenzavirus-3 (bPI3) and human influenza virus (HINF). Plasmids were delivered by intradermal injection into the tails of mice and the types of responses generated were clearly affected by the expressed antigen. Plasmids expressing glycoproteins B and D of BHV-1, and the haemagglutinin/ neuraminidase of bPI3, generated responses with a predominance of IgG1, suggestive of a Th2 type of response. In contrast, the plasmid expressing HINF haemagglutinin induced an antibody response biased towards IgG2a, indicating a Th1 type of response. In most instances the mixing of plasmids had only slight effects on the magnitude or bias of the responses to the individual components. However, under certain conditions we found that addition of a second plasmid converted an IgG2a biased response to a response with primarily IgG1 antibody. The reverse situation (i.e. an IgG1 conversion to IgG2a), however, was not found. These findings have important implications for the development of multivalent vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9880010     DOI: 10.1099/0022-1317-79-12-2965

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Inclusion of the bovine neutrophil beta-defensin 3 with glycoprotein D of bovine herpesvirus 1 in a DNA vaccine modulates immune responses of mice and cattle.

Authors:  Sarah Mackenzie-Dyck; Jennifer Kovacs-Nolan; Marlene Snider; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

2.  Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle.

Authors:  B I Loehr; P Willson; L A Babiuk
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

4.  Modulation of immune responses to bovine herpesvirus-1 in cattle by immunization with a DNA vaccine encoding glycoprotein D as a fusion protein with bovine CD154.

Authors:  Sharmila Manoj; Philip J Griebel; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

5.  A UL47 gene deletion mutant of bovine herpesvirus type 1 exhibits impaired growth in cell culture and lack of virulence in cattle.

Authors:  Vladislav A Lobanov; Sheryl L Maher-Sturgess; Marlene G Snider; Zoe Lawman; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

6.  Stress significantly increases mortality following a secondary bacterial respiratory infection.

Authors:  Paul D Hodgson; Palok Aich; Joseph Stookey; Yurij Popowych; Andrew Potter; Lorne Babiuk; Philip J Griebel
Journal:  Vet Res       Date:  2012-03-21       Impact factor: 3.683

7.  Protective antigens against glanders identified by expression library immunization.

Authors:  Gregory C Whitlock; Mark D Robida; Barbara M Judy; Omar Qazi; Katherine A Brown; Arpaporn Deeraksa; Katherine Taylor; Shane Massey; Andrey Loskutov; Alex Y Borovkov; Kevin Brown; Jose A Cano; Alfredo G Torres; D Mark Estes; Kathryn F Sykes
Journal:  Front Microbiol       Date:  2011-11-21       Impact factor: 5.640

8.  CD335 (NKp46)+ T-Cell Recruitment to the Bovine Upper Respiratory Tract during a Primary Bovine Herpesvirus-1 Infection.

Authors:  Rahwa A Osman; Philip John Griebel
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.